Pharmaceutical News

RSS

Department of Health launches “Immunizations across the Lifespan” campaign

Secretary of Health Everette James today urged all Pennsylvanians to ensure they are fully immunized against vaccine-preventable diseases, noting that August is National Immunization Awareness Month.

31 Jul 2010

FDA announces approval of vaccines for 2010-2011 US influenza season

The U.S. Food and Drug Administration announced today that it has approved vaccines for the 2010-2011 influenza season in the United States.

31 Jul 2010

IQPC's Polymorphism & Crystallization Scientific Forum to address issues on polymorphs

There has been increased focus on using crystals and the ever-changing, sometimes disappearing properties of polymorphs as significant scientific and business opportunities. IQPC's Polymorphism & Crystallization Scientific Forum, taking place October 25- 27, 2010 in Philadelphia, PA will address these issues.

31 Jul 2010

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Vanishing bile duct syndrome refers to a group of disorders characterized by destruction and disappearance of intrahepatic (inside the liver) bile ducts. Multiple causes have been identified including infections, malignancies, autoimmune conditions and adverse effects of medications. The usual course of this condition is variable and many patients with VBDS respond to treatment of the underlying condition and/ or removal of the offending agent. However, others progress to cirrhosis and end stage liver disease requiring liver transplantation.

31 Jul 2010

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Today, Formatech, Inc. announced that it has selected Femta's FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta's upcoming clinical trials.

31 Jul 2010

Sanofi Pasteur announces shipping of Fluzone Influenza Virus Vaccine in the U.S.

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that shipping of the 2010-2011 formulation of its seasonal influenza vaccine Fluzone Influenza Virus Vaccine is underway in the U.S.

31 Jul 2010

Senate panel votes to end drug industry's practice of 'pay-to-delay' generics

The Associated Press: "In a defeat for the powerful drug lobby, a Senate panel approved legislation to prohibit drug companies from paying generic drug makers to delay bringing less costly products to market. … The measure would ban a 'pay-to-delay' practice — opposed by the [Federal Trade Commission] in a series of lawsuits brought since 2001 — in which brand-name drug companies and generic drug makers both profit. Brand-name drug makers get higher prices while the generic companies are paid to stay out of the market."

31 Jul 2010

Consumers who have MMS should stop using it immediately, FDA warns

The U.S. Food and Drug Administration is warning consumers not to take Miracle Mineral Solution, an oral liquid solution also known as "Miracle Mineral Supplement" or "MMS." The product, when used as directed, produces an industrial bleach that can cause serious harm to health.

31 Jul 2010

Lundbeck voluntarily recalls two lots of NeoProfen Injection

Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage. This voluntary recall is the result of the company's inspections of the two product lots of NeoProfen.

31 Jul 2010

GSK anticipates to supply over 30 million doses of FLULAVAL, FLUARIX for 2010-2011 flu season

GlaxoSmithKline announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval® [Influenza Virus Vaccine] allowing distribution in the U.S. to begin for the 2010-2011 flu season. GSK anticipates distribution of Fluarix® [Influenza Virus Vaccine] to follow in the next several weeks.

30 Jul 2010

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the comparable 2009 period.

30 Jul 2010

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Cancer Research UK's Drug Development Office marks the launch of its Biotherapeutics Development Unit (BDU) today (Friday) with the manufacture of its first product - an antibody for treating a range of cancers.

30 Jul 2010

Anadys Pharmaceuticals reports SVR12 data for ANA598

Anadys Pharmaceuticals, Inc. today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12.

30 Jul 2010

Polio cases in India lowest in a decade; Vaccination effort begins in Afghanistan

This year "India has reported the lowest number of polio cases in [the] January-June period ... in a decade," PTI/ZeeTV reports. Twenty-four cases were detected between January and June this year, compared to 151 in the corresponding 2009 period, and 317 in January-June 2008 (7/29).

30 Jul 2010

Amgen second-quarter total revenue increases 2% to $3,804 million

Amgen reported adjusted earnings per share (EPS) of $1.38 for the second quarter of 2010, an increase of 7 percent compared to $1.29 for the second quarter of 2009. Adjusted net income increased 1 percent to $1,326 million for the second quarter of 2010 compared to $1,311 million for the second quarter of 2009.

30 Jul 2010

GSK exercises option to obtain exclusive licence to develop, commercialise GSK '052

Anacor Pharmaceuticals and GlaxoSmithKline PLC today announced that GSK has exercised its option to obtain an exclusive licence to develop and commercialise GSK2251052 (GSK '052), formerly known as AN3365. GSK '052 is a novel, systemic antibiotic derived from Anacor's boron chemistry platform.

30 Jul 2010

Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling

Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA™ was designated an Orphan Drug by the FDA.

30 Jul 2010

Random vaccine distribution prevents spread of disease: Study

The best way to prevent the spread of disease in rural areas may be by targeting select popular hangouts, according to a new study by the Kansas State University EpiCenter research team.The team published "Efficient Mitigation Strategies for Epidemics in Rural Regions" in the July edition of the journal PLoS ONE. The study looks at mitigation strategies based on a contact network model developed using information collected from residents in Clay County, Kan.

30 Jul 2010

Actient Pharmaceuticals completes transaction to license; acquire six pharmaceutical products from UCB

Actient Pharmaceuticals, LLC ,a portfolio company of GTCR, announced today the company successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA, an international biopharmaceutical company based in Brussels, Belgium.

30 Jul 2010

CVS-Aetna deal boosts the drug store chain

Forbes: CVS Caremark, the drug retailer and pharmacy benefit management firm, announced a new agreement with Aetna to help constrain drug costs. "The deal encompasses approximately $9.5 billion in annual drug spending relating to approximately 9.7 million lives. CVS expects significant long-term financial benefits from this strategic relationship" (7/28).

30 Jul 2010

Pharmaceutical News

Department of Health launches “Immunizations across the Lifespan” campaign

FDA announces approval of vaccines for 2010-2011 US influenza season

IQPC's Polymorphism & Crystallization Scientific Forum to address issues on polymorphs

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Sanofi Pasteur announces shipping of Fluzone Influenza Virus Vaccine in the U.S.

Senate panel votes to end drug industry's practice of 'pay-to-delay' generics

Consumers who have MMS should stop using it immediately, FDA warns

Lundbeck voluntarily recalls two lots of NeoProfen Injection

GSK anticipates to supply over 30 million doses of FLULAVAL, FLUARIX for 2010-2011 flu season

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Anadys Pharmaceuticals reports SVR12 data for ANA598

Polio cases in India lowest in a decade; Vaccination effort begins in Afghanistan

Amgen second-quarter total revenue increases 2% to $3,804 million

GSK exercises option to obtain exclusive licence to develop, commercialise GSK '052

Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling

Random vaccine distribution prevents spread of disease: Study

Actient Pharmaceuticals completes transaction to license; acquire six pharmaceutical products from UCB

CVS-Aetna deal boosts the drug store chain

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News